Project Grant R01AI186308
Award Date 9/3/25
Completion Date 8/31/29
Dollars Obligated $2.9M
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
Maryland, USA
Similar Awards
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $774,881 Project Grant under the Allergy and Infectious Diseases Research Federal Grant Program (CFDA 93.855) to The Johns Hopkins University on February 24, 2025. The grant will support research to investigate the use of pro-apoptotic drugs, such as navitoclax, as host-directed therapies for treating pulmonary tuberculosis (TB). The research aims to evaluate how these drugs impact lung immune response, tissue...
- This Project Grant award of $3,145,850.00 was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) federal grant program. The award supports research at The Johns Hopkins University to investigate macrophage senescence as a driver of granuloma failure and necrosis in pulmonary tuberculosis (TB) and TB/HIV coinfection. Key objectives include understanding the role of stress-induced senescence in myeloid...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $429,546 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to National Jewish Health in Colorado. The grant will fund research to evaluate the efficacy of tuberculosis (TB) treatment regimens by analyzing the transcriptomic patterns of Mycobacterium tuberculosis injury and adaptation during drug treatment. The research aims to develop more reliable preclinical measures of TB treatment...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $750,000 Project Grant to The University of Southern Mississippi to research the role of extracellular polyphosphate in Mycobacterium tuberculosis antibiotic tolerance. The 4-year grant, which begins on Sep 20, 2025 and runs through Aug 31, 2029, aims to investigate the metabolic pathways in M. tuberculosis that regulate extracellular...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $832,076 Project Grant under the Allergy and Infectious Diseases Research federal grant program (CFDA 93.855) to the University of Massachusetts Medical School (UMMS) to conduct research on protective CD8 T cell responses to tuberculosis (TB). The research aims to characterize how vaccine-elicited CD8 T cells respond to Mycobacterium tuberculosis (MTB) challenge, identify protective antigens recognized by CD8 T cells,...
- This $193,375 Project Grant, awarded by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855), supports research to identify bacterial determinants that may contribute to variable treatment responses for tuberculosis (TB). The project, conducted by researchers at the Harvard T.H. Chan School of Public Health, aims to investigate the effects of clinically prevalent variants in the ESX1 secretion system on TB...
- The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $224,943 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to the University of Massachusetts to conduct research on "Cell Wall Carbohydrate Recycling in Mycobacterium tuberculosis". The research aims to identify and characterize a novel mechanism for recycling the peptidoglycan component of the Mycobacteriales cell wall, which may promote survival of non-replicating...
- The University of Washington received a $188,760 Project Grant from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research (CFDA 93.855) program. The grant supports research to investigate the role of the lung inflammatory environment and cellular milieu in controlling Mycobacterium tuberculosis (MTB) infection and preventing tuberculosis (TB) disease. Specifically, the research will test the hypothesis that interferon gamma-activated...
- The National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), awarded a $742,499 Project Grant to the University of Alabama at Birmingham (UAB) for the "Molecular Investigation of Siderophore Secretion and Drug Efflux by Mycobacterium Tuberculosis" research project. This 5-year project, running from August 2025 to July 2030, aims to shed light on the unique siderophore secretion system in Mycobacterium...
- This $209,408 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research (CFDA 93.855) program, supports a research project to characterize the role of unconventional T cell subsets in the immune response to Mycobacterium tuberculosis (MTB) infection using a non-human primate model. The goal is to gain a better understanding of these niche T cell populations in the lung granulomas during the early stages of MTB...
The National Institute of Allergy and Infectious Diseases (NIAID) awarded a $2,922,220 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to The Johns Hopkins University. The grant supports research to advance apoptosis-inducing agents as host-directed therapy for tuberculosis (TB). The research aims to boost host immune responses via the intrinsic apoptosis pathway to reduce Mycobacterium tuberculosis (MTB) growth and enhance the bactericidal activity of first-line anti-TB regimens. The project period runs from Sep 3, 2025 to Aug 31, 2029.
Generated 10/21/25, 5:34 AM
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.9m | 9/2/25 |